Update on the diagnosis and treatment of hospital-acquired pneumonia

Formulary

Volumn 43, Issue 7, 2008, Pages 250-258

  Magiorakos, Annapelle ^a   Golik, Monica V ^a,b   Lawrence, Kenneth R ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b WATERBURY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; GENTAMICIN; ICLAPRIM; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIGECYCLINE; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL COLONIZATION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG CHOICE; DRUG DOSE REGIMEN; ENDOTRACHEAL INTUBATION; ENTEROBACTER; ENTEROBACTER INFECTION; EXTUBATION; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEALTHCARE ASSOCIATED PNEUMONIA; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INFECTIOUS PNEUMONIA; INFLUENZA; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGICAL EXAMINATION; MONOTHERAPY; MORBIDITY; MORTALITY; NON INVASIVE MEASUREMENT; PATHOGENESIS; PRACTICE GUIDELINE; PROTEUS; PSEUDOMONAS AERUGINOSA; RISK ASSESSMENT; SERRATIA MARCESCENS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TREATMENT DURATION; TREATMENT OUTCOME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 48249118435     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Craven DE. Preventing ventilator-associated pneumonia in adults: Sowing seeds of change. Chest. 2006;130:251-260.
2. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med. 2002;165:867-903.
3. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest. 2006;129:1210-1218.
4. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416.
5. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest. 1999;115:462-474.
6. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: Getting it right the first time. Drugs. 2003;63:2157-2168.
7. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998;129:433-440.
8. Fagon JY, Chastre J. Antimicrobial treatment of hospital-acquired pneumonia. Clin Chest Med. 2005;26:97-104.
9. Heyland DK, Cook DJ, Griffith L, Keenan SP, Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med. 1999;159:1249-1256.
10. Rello J. Bench-to-bedside review. Therapeutic options and issues in the management of ventilator-associated bacterial pneumonia. Crit Care. 2005;9:259-265.
11. Bonten MJ, Kollef MH, Hall JB. Risk factors for ventilator-associated pneumonia: From epidemiology to patient management. Clin Infect Dis. 2004;38:1141-1149.
12. Isakow W, Kollef MH. Preventing ventilator-associated pneumonia: An evidence-based approach of modifiable risk factors. Semin Respir Crit Care Med. 2006;27:5-17.
13. Weber DJ, Rutala WA, Sickbert-Bennett EE, Samsa GP, Brown V, Niederman MS. Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. Infect Control Hosp Epidemiol. 2007;28:825-831.
14. Sopena N, Sabria M; Neunos 2000 Study Group. Multicenter study of hospital-acquired pneumonia in non-ICU patients. Chest. 2005;127:213-219.
15. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: A single-center experience. Antimicrob Agents Chemother. 2007;51:3568-3573.
16. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of healthcare-associated pneumonia: Results from a large US database of culture-positive pneumonia. Chest. 2005;128:3854-3862.
17. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 1999;160:608-613.
18. Kollef MH. Antibiotic management of ventilator-associated pneumonia due to antibiotic-resistant gram-positive bacterial infection. Eur J Clin Microbiol Infect Dis. 2005;24:794-803.
19. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med. 1998;157:531-539.
20. Fagon JY, Chastre J, Hance AJ, Domart Y, Trouillet JL, Gibert C. Evaluation of clinical judgment in the identification and treatment of nosocomial pneumonia in ventilated patients. Chest. 1993;103:547-553.
21. Fabregas N, Ewig S, Torres A, et al. Clinical diagnosis of ventilator associated pneumonia revisited: Comparative validation using immediate post-mortem lung biopsies. Thorax. 1999;54:867-873.
22. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med. 2000;132:621-630.
23. Baughman RP. Microbiologic diagnosis of ventilator-associated pneumonia. Clin Chest Med. 2005;26:81-86.
24. Canadian Critical Care Trials Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med. 2006;355:2619-2630.
25. Shorr AF, Sherner JH, Jackson WL, Kollef MH. Invasive approaches to the diagnosis of ventilator-associated pneumonia: A meta analysis. Crit Care Med. 2005;33:46-53.
26. Determann RM, Millo JL, Gibot S, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med. 2005;31:1495-1500.
27. Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. Eur Respir J. 2008;31:356-362.
28. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest. 2002;122:262-268.
29. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888-1895.
30. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113:412-420.
31. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med. 1996;22:387-394.
32. Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36:737-744.
33. Jones RN, Huynh HK, Biedenbach DJ, Fritsche TR, Sader HS. Doripenem (S-4661), a novel carbapenem: Comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J Antimicrob Chemother. 2004;54:144-154.
34. Rea-Neto A, Niederman M, Lee M, Kaniga K, Prokocimer P, Friedland I. Efficacy and safety of intravenous doripenem vs. piperacillin-tazobactam in nosocomial pneumonia [abstract]. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 17-20, 2007; Chicago, IL. Abstract L-431.
35. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med. 2008;36:1089-1096.
36. New drug application submitted for investigational antibiotic doripenem [press release]. Raritan, NJ: Ortho-McNeil; June 6, 2007.
37. Pankey GA. Tigecycline. J Antimicrob Chemother. 2005;56:470-480.
38. Wyeth data on file, 2007.
39. Wyeth receives approvable letter from FDA for tygacil for the treatment of patients with community-acquired pneumonia [press release]. Collegeville, PA: Wyeth Pharmaceuticals; May 29, 2008.
40. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care. 2006;12:452-457.
41. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109-1115.
42. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32:2183-2190.
43. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA. 2003;290:2588-2598.
44. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med. 2003;31:676-682.
45. CMS proposes to expand quality program for hospital inpatient services in FY 2009 [press release]. Baltimore, MD: Centers for Medicare and Medicaid Services; April 14, 2008.
46. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis. 2007;45:1179-1181.
47. Clinical efficacy of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia. clinicaltrials.gov website. http://clinicaltrials. gov/ct2/show/nct00543608?term=pneumonia& rank=4. Accessed June 21, 2008.
48. Ceftobiprole in the treatment of hospital-acquired pulmonary infections. clinicaltrials.gov website. http://clinicaltrials.gov/ct2/show/nct00229008?intr =%22methicillin%22. Accessed June 21, 2008.
49. Tolentino-DelosReyes AF, Ruppert SD, Shiao SY. Evidence-based practice: Use of the ventilator bundle to prevent ventilator-associated pneumonia. Am J Crit Care. 2007;16:20-27.